# To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.

> **NCT05925452** · NA · RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 221 (estimated)

## Conditions studied

- Active Systemic Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** GenaKumab

## Key facts

- **NCT ID:** NCT05925452
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2028-03-24
- **Final completion:** 2028-06-29
- **Target enrollment:** 221 (ESTIMATED)
- **Last updated:** 2024-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05925452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05925452, "To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05925452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*